Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer
- Authors:
- Naomi Serling‑Boyd
- Zoe Quandt
- Nazima Allaudeen
View Affiliations
Affiliations: Department of Medicine, Stanford Hospital and Clinics, Stanford, CA 94305, USA, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA, Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
- Published online on: March 8, 2017 https://doi.org/10.3892/mco.2017.1186
-
Pages:
589-592
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, with most cases occurring in hematological malignancies following the initiation of treatment. However, on rare occasions, TLS may occur in solid tumors as well. In the present case study, the case is reported of a 56‑year‑old African‑American man who presented with a recent diagnosis of prostate cancer, abdominal pain, elevated transaminases, renal insufficiency, hyperkalemia, and hyperuricemia, consistent with spontaneous TLS in the setting of metastatic prostate cancer. A computed tomography scan of the patient's abdomen demonstrated diffuse metastatic tumor burden. Following treatment with allopurinol, rasburicase, and initiation of anti‑androgen therapy for the prostate cancer, the patient's TLS laboratory results normalized, however, his renal functions continued to decline. TLS is rare in solid tumors, and particularly rare in prostate cancer, with only six other case reports of the syndrome occurring to the best of our knowledge. This case report highlights the need for early recognition of TLS, even in cases that are not typically associated with the syndrome, as prompt diagnosis will affect early management and may be able to prevent or minimize complications.
View References
1
|
Mirrakhimov AE, Ali AM, Khan M and
Barbaryan A: Tumor lysis syndrome in solid tumors: An up to date
review of the literature. Rare Tumors. 6:53892014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Vaisban E, Braester A, Mosenzon O, Kolin M
and Horn Y: Spontaneous tumor lysis in solid tumors: Really a rare
condition? Am J Med Sci. 325:38–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
3
|
Wilson FP and Berns JS: Onco-Nephrology:
Tumor lysis syndrome. Clin J Am Soc Nephrol. 7:1730–1739. 2012.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Cairo MS and Bishop M: Tumor lysis
syndrome: New therapeutic strategies and classification. Br J
Haematol. 127:3–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kaplan MA, Kucukoner M, Alpagat G and
Isikdogan A: Tumor lysis syndrome during radiotherapy for prostate
cancer with bone and bone marrow metastases without visceral
metastasis. Ann Saudi Med. 32:306–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lin CJ, Hsieh RK, Lim KH, Chen HH, Cheng
YC and Wu CJ: Fatal spontaneous tumor lysis syndrome in a patient
with metastatic, androgen-independent prostate cancer. South Med J.
100:916–917. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sorscher SM: Tumor lysis syndrome
following docetaxel therapy for extensive metastatic prostate
cancer. Cancer Chemother Pharmacol. 54:191–192. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tanvetyanon T and Choudhury AM: Fatal
acute tumor lysis syndrome, hepatic encephalopathy and flare
phenomenon following combined androgen blockade. J Urol.
171:16272004. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wright JL, Lin DW, Dewan P and Montgomery
RB: Tumor lysis syndrome in a patient with metastatic, androgen
independent prostate cancer. Int J Urol. 12:1012–1013. 2005.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Mazzoni S: Tumor lysis syndrome in
anti-androgen-treated metastatic prostate cancer. Int Urol Nephrol.
48:1837–1838. 2016. View Article : Google Scholar : PubMed/NCBI
|
11
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA: Grading Committee: The 2014
International Society of Urological Pathology (ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma: Definition of
Grading Patterns and Proposal for a New Grading System. Am J Surg
Pathol. 40:244–252. 2016.PubMed/NCBI
|